Tag Archives: GI & liver

Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis

Sachar, Hamita, KetaVaidya, and LorenLaine. “Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis.” JAMA internal medicine 174.11 (2014):1755-62. Conclusion: “Intermittent PPI therapy is comparable to the current guideline-recommended regimen of intravenous bolus … Continue reading

Posted in Applying evidence, EUH, Therapy | Tagged

Checking Hepatitis B surface antigen levels after treatment

HBsAg levels at 6 months of LMV-ADV combination therapy can help predict treatment response. More potent treatments should be considered for cases positive for HBeAg, with high baseline HBV DNA and high HBsAg levels after 6 months treatment. Kim, Jeong … Continue reading

Posted in EUHMidtown | Tagged

Approach to abnormal liver function tests

Note: Figures and table numbers appear above the figures and tables and taken from the following source. Woreta TA1, Alqahtani SA. Evaluation of abnormal liver tests. Med Clin North Am. 2014 Jan;98(1):1-16. Table 1. Categorization of liver diseases by pattern of elevation of liver … Continue reading

Posted in Background question, Diagnosis, EUH, Therapy | Tagged

Diantamoeba fragilis as a cause of gastrointestinal (GI) clinical symptoms such as diarrhea

Bottom line: Numerous reports from all over the world describe associations between diantamoeba fragilis and various GI symptoms, such as diarrhea. Evidence: Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J. A review of the clinical presentation … Continue reading

Posted in Applying evidence, Diagnosis, EUH | Tagged ,

What is the link between deep venous thrombosis and inflammatory bowel disease?

Thrombotic mechanism in inflammatory bowel disease patients is complex, multifactorial and not fully understood. Acquired risk factors for thrombosis, often present in inflammatory bowel disease patients, only partially explain increased thrombotic risk. No relevant association has been found regarding genetic … Continue reading

Posted in VA | Tagged

What is the relationship between Neutrophil gelatinase-associated lipocalin and hepatorenal syndrome?

The Bottom Line: This study included 64 patients with cirrhosis and 23 control subjects. Patients with type 1 and type 2 HRS had significantly higher plasma and urine NGAL levels compared with stable cirrhosis and control subjects. This study concluded … Continue reading

Posted in VA | Tagged

What is ELAD?

An investigational biologic treatment for patients with acute liver failure.  It uses cells derived from the patient’s liver to remove toxins from and deliver nutrients to the patient’s blood during processing outside the patient’s body.  The aim is to stabilize … Continue reading

Posted in Background question, EUH | Tagged